Fierce Pharma
OCTOBER 3, 2024
Eli Lilly’s juggernaut diabetes and obesity drugs Mounjaro and Zepbound have been erased from the FDA’s shortage list, | Eli Lilly’s juggernaut diabetes and obesity drugs Mounjaro and Zepbound have been erased from the FDA’s shortage list, freeing the company from competing with compounding pharmacies that have been producing copycat versions of the in-demand treatments.
MedCity News
OCTOBER 3, 2024
More investors are becoming interested in digital health startups specifically targeting youth behavioral health. However, there are still more opportunities to reach youth on Medicaid. The post Funding In Youth Mental Health Is Growing. Where are the Opportunities? appeared first on MedCity News.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Fierce Pharma
OCTOBER 3, 2024
Armed with what it sees as impressive clinical data and bolstered by long-standing ties to the Niemann-Pick disease type C (NPC) community, Zevra Therapeutics is confident that its new drug Miplyff | Armed with what it sees as impressive clinical data and bolstered by long-standing ties to the Niemann-Pick disease type C community, Zevra Therapeutics is confident that its new drug Miplyffa can become the “foundation and the cornerstone” for treatment of the debilitating rare disease going forwar
MedCity News
OCTOBER 3, 2024
AI startups should be thoughtful about which healthcare market(s) they’re going after, according to investors at Bessemer Venture Partners. Healthcare AI startups seeking venture capital face heightened expectations for scale, which requires access to substantial total addressable markets. The post How Can AI Startups Navigate Healthcare’s Fragmented Landscape?
Advertisement
What if you could help your sellers stop wasting 72% of their day on non-selling activities and focus on bringing in revenue? Incorporating AI in your enablement workflows can help you cut down on busy work, get projects done faster, and let your team (and you!) focus on making a bigger impact. We put together this guide to show you how to use AI to cut time and costs for projects, including collateral creation, development of training videos, and automating tedious processes.
Fierce Pharma
OCTOBER 3, 2024
On its way to becoming the most highly anticipated approval of 2024, BMS’ schizophrenia treatment Cobenfy has had an unusual but instructive odyssey.
MedCity News
OCTOBER 3, 2024
The Hippocratic oath can’t stop with direct patient care; the healthcare industry and its key stakeholders must address persistent public health problems systematically. We have the tools to reduce medication harm by half or more; it is long past time to make this a public health priority. The post First Do No Harm: Support Legislative Efforts to Combat the Adverse Drug Event Epidemic appeared first on MedCity News.
Pharma Rep Focus brings together the best content for pharma rep professionals from the widest variety of industry thought leaders.
MedCity News
OCTOBER 3, 2024
Laboratory construction has waned in the past two years due to the end of the pandemic and an economic slowdown, according to a new report from CBRE. The firm predicts in-progress lab construction will decline to pre-pandemic levels by 2026. The post CBRE Report: Post-Pandemic Slowdown Now Evident in Oversupply of Biotech Labs appeared first on MedCity News.
Fierce Pharma
OCTOBER 3, 2024
As the BIOSECURE Act works its way through the U.S. legislative branch, two companies named in the bill are reportedly weighing sales of certain units and facilities. | WuXi AppTec has put its cell and gene therapy manufacturing arm, WuXi Advanced Therapies, on the market, The Financial Times reported Thursday. At the same time, WuXi Biologics is working with advisors to gauge interest in some of its European production facilities, the news outlet added, citing sources.
MedCity News
OCTOBER 3, 2024
Providers should incorporate mental health screenings as a standard part of cancer care for patients and their loved ones. The post Shock, Fear and Anxiety – The Complexity of Breast Cancer Beyond Diagnosis appeared first on MedCity News.
Fierce Pharma
OCTOBER 3, 2024
As officials consider how to distribute Eli Lilly’s Mounjaro to a nation that has a rapidly growing (PDF) o | As officials consider how to distribute Eli Lilly’s Mounjaro to a nation that has a rapidly growing obesity problem, England’s National Health Service is proposing that those who need it most should get it first.
Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.
The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven
pharmaphorum
OCTOBER 3, 2024
Gilead has partnered with six generic manufacturers to expand access to HIV Drug lenacapavir in high-incidence, resource-limited countries following promising clinical trial results.
Fierce Pharma
OCTOBER 3, 2024
With a recently acquired FDA nod for its Halozyme Therapeutics-partnered Vyvgat Hytrulo, argenx is looking to take Halozyme’s delivery tech to new heights through a $30 million licensing deal that | The company's collaboration with drug delivery partner Halozyme Therapeutics now totals six targets and could result in milestone payments of up to $85 million per target for Halozyme.
pharmaphorum
OCTOBER 3, 2024
Proscia announces launch of Concentriq Embeddings and Proscia AI Toolkit, hoping to accelerate precision medicine R&D.
Fierce Pharma
OCTOBER 3, 2024
After unlocking commercial supply and enlisting a manufacturing partner earlier this year, Ferring Pharmaceuticals has reached a new turning point on its quest to satisfy current and future demand | Ferring on Thursday opened a new global manufacturing hub in Kuopio, Finland, to help produce drug substance for Adstiladrin, which was approved by the FDA in late 2022 as the first gene therapy to target high-risk and non-muscle invasive bladder cancer in patients who no longer respond to therapy.
Advertisement
Every marketer knows how important it is to prove their efforts drive sales opportunities, but that’s easier said than done. When problems like sales and marketing misalignment, lack of data, and wasted efforts persist, marketers can’t measure, prove, or increase their impact on revenue at a time when demonstrating marketing value is critical. Using analyst and expert data, this guide to marketing impact and content attribution explains: How B2B buyers use content The most common types of conten
PharmaTimes
OCTOBER 3, 2024
Phase 1 trial of IRL757 demonstrates good absorption and safety profile
Fierce Pharma
OCTOBER 3, 2024
On the same day as Roche's Pharma Day in London, the biopharma giant revealed a high-dollar deal with Chinese-American biotech Regor for the latter's CDK inhibitors. | On the same day as Roche's Pharma Day in London, the drugs giant struck a high-dollar deal with Chinese-American biotech Regor for the latter's CDK inhibitors. Legend's momentum continued with a strong survival showing for Johnson & Johnson-partnered Carvykti and the announcement of a planned R&D f
Pharmaceutical Technology
OCTOBER 3, 2024
GLP-1 RAs are being recommended on social media, raising questions about who can see the content and what the effects might be.
Fierce Pharma
OCTOBER 3, 2024
Omnichannel marketing has proven itself as a powerful strategy across industries, and healthcare and pharma are no excep | In this insightful episode, we sit down with Jaclene Johnson, Vice President at Tandem, a leading precision healthcare marketing technology firm, to explore how omnichannel can be effectively harnessed by professionals in the healthcare space.
PharmaTech
OCTOBER 3, 2024
Pharmaceutical Technology sat down with Erica Schlesinger, vice president of technical development at Serán Bioscience, to talk about her upcoming presentation at AAPS PharmSci 360 2024, “High Dose Subcutaneous Delivery of Protein Therapeutics.
Fierce Pharma
OCTOBER 3, 2024
“I’m sure if you were to sit anybody else in this chair, they lead with AI. I will too,” said Steven Carickhoff, president of BioPharm Communications, at Digital Pharma East. | In this interview, the President of Biophonic Communication discusses how AI is transforming clients’ commercial models by improving data integration, speeding up product launches, and identifying key therapeutic areas.
pharmaphorum
OCTOBER 3, 2024
A new report commissioned by ABPI found hospitals engaging in industry partnerships more likely to follow NICE recommendations.
Fierce Pharma
OCTOBER 3, 2024
Matthew Walsh, General Manager of Biopharma at ixlayer - the leading cloud-based platform powering an end-to-end, direct-to-patient healthcare solution - sat down with Fierce at Digital Phar | Matthew Walsh, General Manager of Biopharma at Ixlayer – a cloud-based platform specialist empowering operational efficiency, patient access, and improved outcomes – sat down with Fierce at Digital Pharma East.
Advertisement
Quotas need to be hit. Revenue goals need to be met. This reality makes shortening sales onboarding time a top priority. Organizations with a standard onboarding process boost employee retention by 58% and increase productivity by 50%. Unfortunately, many companies struggle with inefficient processes that lead to high turnover and missed revenue opportunities.
PharmaTimes
OCTOBER 3, 2024
Largest real-world study demonstrates significant survival advantage
Pharmaceutical Technology
OCTOBER 3, 2024
GLP-1 RAs are being recommended on social media, raising questions about who can see the content and what the effects might be.
pharmaphorum
OCTOBER 3, 2024
Discover the key takeaways from the LSX USA Congress with this podcast wrap-up, offering insights into investment outlook and trends discussed at the event.
Pharmaceutical Commerce
OCTOBER 3, 2024
Why it's critical for companies to set long-term, strategic goals in their journeys toward decarbonization.
Pharmaceutical Technology
OCTOBER 3, 2024
Pfizer and Merck KGaA’s venture capital arms were among the backers in the Series B round.
European Pharmaceutical Review
OCTOBER 3, 2024
Ferring Pharmaceuticals has opened a new European manufacturing site focused on supporting production for one of its gene therapies to treat non-muscle invasive bladder cancer (NMIBC). The global manufacturing hub in Kuopio, Finland will bolster supply of the drug substance of its gene therapy Adstiladrin ® (nadofaragene firadenovec-vncg). The treatment is the first and only US Food and Drug Administration (FDA)-approved intravesical non-replicating gene therapy for adults with high-risk Bacillu
Pharmacy Times
OCTOBER 3, 2024
Fedratinib is an orally available, small molecule inhibitor of JAK-2 approved for treatment of myelofibrosis.
European Pharmaceutical Review
OCTOBER 3, 2024
Articles in Issue 4 of European Pharmaceutical Review include: FOREWORD The FDA’s new mandate on Burkholderia cepacia complex (BCC) testing: implications for non-sterile drug products Dave Elder David P Elder Consultancy REGULATORY INSIGHT ECCTA: cracking down on fraud in the life sciences sector Quinton Newcomb and Farheen Ishtiaq-Stansfeld Fieldfisher ENVIRONMENTAL MONITORING Best practices in environmental monitoring of compressed gas ports Ryan Brough, Peter Lisowski and Alicia Vieau C
Advertisement
Are your sellers unsure about using AI in their day-to-day workflows? Or are they eager to try but uncertain where to start? They might be asking: Which tasks are best suited for AI? How will using AI affect my relationship with my customers? With so many tools available, which ones are the most useful to me? To help answer these and other common questions about using AI during the sales cycle, we surveyed B2B sellers who were early adopters to get their insight and advice about how to use gen A
Expert insights. Personalized for you.
312 
Let's personalize your content